Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial. J of Skin. 2020;4(6):s102. doi:10.25251/skin.4.supp.102